Furthermore, METTL1 can directly influence tumor responsiveness to immunotherapy by regulating key immune checkpoints (e.g., PD-L1, CTLA-4), immune regulatory molecules (modulating interferon signaling), and proinflammatory immune cell activity, indicating its potential as a therapeutic target. This evidence concerns the gene CD274 and neoplasm.